TuHURA Biosciences strengthens its intellectual property portfolio with a new U.S. patent covering its DOR ADC platform, expanding potential applications into CAR-T and other cellular immunotherapies.
TuHURA Biosciences has significantly bolstered its intellectual property portfolio through the receipt of a key U.S. patent covering its DOR ADC technology. The patent is strategically significant as it extends the potential application of the company's technology beyond traditional antibody-drug conjugates to include advanced cellular immunotherapies such as CAR-T, Tregs, and TIL cell therapies.
The patent covers the use of TuHURA's DOR ADC technology in applications beyond ADCs, specifically including autologous or allogeneic adoptive cellular immunotherapies like CAR-T, Tregs, and TIL cell therapies.
TuHURA Biosciences (NASDAQ: HURA) has been granted a new U.S. patent covering its proprietary DOR ADC technology. The intellectual property extends beyond antibody-drug conjugates to include applications in adoptive cellular immunotherapies, such as CAR-T and TIL cell therapies, bolstering the company's clinical development pipeline.
The patent covers the company's DOR ADC technology and its application in various adoptive cellular immunotherapies, including CAR-T, Tregs, and TIL cell therapies.